These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 33385331)

  • 21. Inhibition of the αvβ6 integrin leads to limited alteration of TGF-α-induced pulmonary fibrosis.
    Madala SK; Korfhagen TR; Schmidt S; Davidson C; Edukulla R; Ikegami M; Violette SM; Weinreb PH; Sheppard D; Hardie WD
    Am J Physiol Lung Cell Mol Physiol; 2014 Apr; 306(8):L726-35. PubMed ID: 24508732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo.
    Eberlein C; Kendrew J; McDaid K; Alfred A; Kang JS; Jacobs VN; Ross SJ; Rooney C; Smith NR; Rinkenberger J; Cao A; Churchman A; Marshall JF; Weir HM; Bedian V; Blakey DC; Foltz IN; Barry ST
    Oncogene; 2013 Sep; 32(37):4406-16. PubMed ID: 23108397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer.
    Cha JH; Chan LC; Wang YN; Chu YY; Wang CH; Lee HH; Xia W; Shyu WC; Liu SP; Yao J; Chang CW; Cheng FR; Liu J; Lim SO; Hsu JL; Yang WH; Hortobagyi GN; Lin C; Yang L; Yu D; Jeng LB; Hung MC
    J Biol Chem; 2022 Apr; 298(4):101817. PubMed ID: 35278434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by αvβ6 integrin-mediated signaling in ovarian cancer.
    Xue B; Wu W; Huang K; Xie T; Xu X; Zhang H; Qi C; Ge J; Yu Y
    Mol Cell Biochem; 2013 Aug; 380(1-2):177-84. PubMed ID: 23615713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of endoplasmic reticulum stress alleviates triple-negative breast cancer cell viability, migration, and invasion by Syntenin/SOX4/Wnt/β-catenin pathway via regulation of heat shock protein A4.
    Nan J; Hu X; Guo B; Xu M; Yao Y
    Bioengineered; 2022 Apr; 13(4):10564-10577. PubMed ID: 35442158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells.
    Takasaka N; Seed RI; Cormier A; Bondesson AJ; Lou J; Elattma A; Ito S; Yanagisawa H; Hashimoto M; Ma R; Levine MD; Publicover J; Potts R; Jespersen JM; Campbell MG; Conrad F; Marks JD; Cheng Y; Baron JL; Nishimura SL
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
    Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrin α9 depletion promotes β-catenin degradation to suppress triple-negative breast cancer tumor growth and metastasis.
    Wang Z; Li Y; Xiao Y; Lin HP; Yang P; Humphries B; Gao T; Yang C
    Int J Cancer; 2019 Nov; 145(10):2767-2780. PubMed ID: 31008533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy induces enrichment of CD47
    Samanta D; Park Y; Ni X; Li H; Zahnow CA; Gabrielson E; Pan F; Semenza GL
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1239-E1248. PubMed ID: 29367423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.
    Parvani JG; Gujrati MD; Mack MA; Schiemann WP; Lu ZR
    Cancer Res; 2015 Jun; 75(11):2316-2325. PubMed ID: 25858145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrin αvβ6 promotes an osteolytic program in cancer cells by upregulating MMP2.
    Dutta A; Li J; Lu H; Akech J; Pratap J; Wang T; Zerlanko BJ; FitzGerald TJ; Jiang Z; Birbe R; Wixted J; Violette SM; Stein JL; Stein GS; Lian JB; Languino LR
    Cancer Res; 2014 Mar; 74(5):1598-608. PubMed ID: 24385215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of αvβ6 downregulates P-glycoprotein and sensitizes multidrug-resistant breast cancer cells to anticancer drugs.
    Zhang YH; Gao ZF; Dong GH; Li X; Wu Y; Li G; Wang AL; Li HL; Yin DL
    Neoplasma; 2020 Mar; 67(2):379-388. PubMed ID: 32039627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway.
    Xie W; Zhao H; Wang F; Wang Y; He Y; Wang T; Zhang K; Yang H; Zhou Z; Shi H; Wang J; Huang G
    J Exp Clin Cancer Res; 2021 Jan; 40(1):30. PubMed ID: 33436039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.
    Sceneay J; Goreczny GJ; Wilson K; Morrow S; DeCristo MJ; Ubellacker JM; Qin Y; Laszewski T; Stover DG; Barrera V; Hutchinson JN; Freedman RA; Mittendorf EA; McAllister SS
    Cancer Discov; 2019 Sep; 9(9):1208-1227. PubMed ID: 31217296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
    Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.